
GET READY FOR THE

ADVOCACY LIMB GIRDLE MUSCULAR DYSTROPHY S

At the **2022 LGMD Global Advocacy Summit**, a first for the limb-girdle community, you will learn directly from pharmaceutical companies about the clinical trials coming in 2022 and 2023. Additionally, you will hear from patient advocacy leaders from around the world about the regulatory drug process in both the U.S. and Europe. You will also have the opportunity to listen to LGMD patients and caregivers share with the invited companies about what matters most to them in trials and in drug development. You do not want to miss it!

SUMMIT SCHEDULE | MAY 20,2022 | 12:00 PM - 7:00 PM



WATCH THE LIVESTREAM EVENT AT WWW.MALONE-MEDIA.COM/VIDEOS/LGMDSUMMIT

1:45 PM **US Advocacy** In this session, you will gain insight on the various structures so you can be an effective voice for LGMD. You will also learn from start to finish and find out how you can be involved. Paul Melmever | Vice President, Public Policy and Advocacy, Musc Sharon Hesterlee | Chief Research Officer, Muscular Dystrophy As **0&A** Brad Williams, PhD | Director of Research & Diagnostic Innovation, Jain Foundation (USA) 2:45 PM **US Updates** Hear updates from the Principal Investigator of the GRASP-Nicholas Johnson, MD, MSci, FAAN | Virginia Commonwealth Univ **Research Updates for LGMD2B/R2** Listen to research updates and information about preclinica Douglas E. Albrecht, PhD | Co-President, Jain Foundation (USA) 3:00 PM **Roundtable Discussion 2** In our second roundtable discussion for the Summit, you to share their voices with the companies designing clinica **Moderator: Kathryn Bryant Knudson** | Founder/CEO, The Speak Moderator: Sarah Foye | Founder/Organizer, Team Titin (USA) 3:30–7:00 PM Pharmaceutical Updates 3:30 PM Sarepta Therapeutics. Inc. S A R E P T A Sarepta will present updates on their gene therapy deve Louise Rodino-Klapac, PhD | Executive Vice President, Head of R8 4:00 PM Atamyo Therapeutics Atamyo will share on their upcoming gene therapy trial fo programs for other LGMDs. **Sophie Olivier, MD** Chief Medical Officer (France) 4:30 PM Vita Therapeutics Vita Therapeutics will offer information about their platfo to file a first-in-human IND study later this year. Douglas Falk, MS | Cofounder and Chief Executive Officer (USA) Steve Brooks, MD, MBA | Senior Vice President, Regulatory Affair 5:00 PM Asklepios BioPharmaceutical, Inc. (AskBio) Hear from the AskBio team about their current clinical stud for individuals with a confirmed genetic diagnosis of LGME 5:30 PM ML Bio Solutions The team at ML Bio Solutions will be sharing on their de treatment for patients with LGMD2I/R9. Doug Sproule, MD, MSc | Chief Medical Officer (USA) **6:00 PM Edgewise Therapeutics** Edgewise Therapeutics will share about their current pip muscle proteins to address LGMD. Alan Russell, PhD | Chief Scientific Officer (USA) 6:30 PM Myogenica Hear from a professor at the University of Minnesota about of iPSC-derived myogenic progenitors for the treatment of

Rita Perlingeiro, PhD | Cofounder (USA)

7:00 PM

Closing

ALL TIMES ARE IN EASTERN DAYLIGHT TIME (EDT), UTC -4. | Summit schedule is subject to change.

SUMMIT SCHEDULE | MAY 20,2022 | 12:00 PM - 7:00 PM

that exist in the United States for patient advocacy about the drug development and regulatory process ular Dystrophy Association (MDA) (USA) sociation (MDA) (USA)	Paul Melmeyer Sharon Hesterlee, PhD
 Sarah Shira Emmons Director & Community Strategies, Jain Fot 	
.GMD Consortium about active studies and clinical tria ersity: Principal Investigator, GRASP-LGMD Consortium (USA)	Ils. Nicholas Johnson, MD, MSci, FAAN
Il progress for LGMD2B/R2. Laura Rufibach, PhD Co-Presid	dent, Jain Foundation (USA)
vill hear from four more individuals who are ready I trials and developing treatment drugs for LGMD. Foundation (USA) Rachel DeConti I (USA)	 John Faver I (USA) Keisha Greaves I (USA)
c lopment programs for multiple LGMD subtypes. AD and Chief Scientific Officer (USA)	Louise Rodino-Klapac, PhD
r LGMD2I/R9, as well as their plans for their next	Sophie Olivier, MD
rm and plans for LGMD2A/R1, as well as their goal	
s (USA)	Doug Falk, MS Steve Brooks, MD, MBA
dy (LION-CS101) of an investigational gene therapy 21/R9.	
velopment of BBP-418, potentially the first oral	Doug Sproule, MD, MSc
eline of precision therapeutics that regulate key	Alan Russell, PhD
preclinical studies to enable a phase 1 clinical trial muscular dystrophies.	Rita Perlingeiro, PhD